Abstract
Each year the physician-editors of Journal Watch Cardiology select the stories published during that year that they believe had the greatest impact on cardiovascular diagnosis and treatment. Here are highlights from our choices for 2006. Several important studies addressed strategies involving clopidogrel. In the CHARISMA trial, the addition of clopidogrel to aspirin did not improve outcomes in high-risk, stable patients. In the ACTIVE W trial, clopidogrel plus aspirin was inferior to oral anticoagulation therapy in preventing stroke, systemic embolism, MI, or vascular death …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
